Type I interferons, including INF-γ and INF-α, have been used for several years to inhibit NLRP3 and other inflammatory bodies in various autoimmune and autoinflammatory diseases, and INF-γ was significantly upregulated in ulcerative colitis (p < 0.001) to activate the NLRP3 inflammasome, which promotes inflammation. Here, NLRP3 is linked to ulcerative colitis.